Last Update 01 Apr 26

Fair value Decreased 0.098%

BMRN: Pending Amicus Deal Will Reshape Earnings Power Despite Treatment Franchise Risks

Analyst revisions point to a slightly lower blended fair value for BioMarin Pharmaceutical, trimming the price target by about $0.09 as analysts factor in mixed views on Voxzogo and the pending Amicus deal while keeping underlying growth, margin, and P/E assumptions broadly unchanged.

Analyst Commentary

Recent Street research reflects a split view on BioMarin, with most analysts still constructive on long term value creation while others focus on Voxzogo related risks and competitive pressures. Price targets cluster in a wide range from $55 to $105, which underscores differing opinions on execution around the Amicus acquisition, the durability of the Voxzogo franchise, and the contribution from the enzyme portfolio and earlier stage pipeline.

Bullish Takeaways

Bullish analysts see the pending Amicus acquisition as a key value driver, updating models to include the combined company and treating the deal close as a potential offset to Voxzogo and Roctavian headwinds.
Several firms raise price targets into the $94 to $105 range, tying upside to contributions from indication expansion for Voxzogo, the broader enzyme franchise, and early readthrough from assets like BMN 351 as these move through the clinic.
Some commentary highlights BioMarin as undervalued relative to its cash generation profile, pointing to 2025 operating cash flow of $828m as support for the current equity value and for ongoing investment in the pipeline.
Positive views around Voxzogo are not uniform, but a subset of bullish analysts regard the recent safety related trial discontinuations as more indication specific and see the overall equity story as less reliant on this single asset over time.

Bearish Takeaways

Bearish analysts voice concern that consensus assumptions for sustained Voxzogo growth through 2030 underestimate upcoming disruption from a once weekly injectable competitor in the U.S. and a once daily oral option, which they expect to pressure the franchise.
Several firms trim price targets into the mid $80s or lower, citing below consensus guidance for future Voxzogo sales, softer product sales guidance for Voxzogo compared with enzymes, and the likely impact of competitors as reasons to dial back expectations.
One neutral stance with a $55 target reflects a view that the market may still not fully price in competitive risk to Voxzogo and that current models could prove too optimistic if switching to rival regimens accelerates.
While some analysts highlight upcoming data readouts and deal closing milestones as potential positives, others see this busy news period as a source of execution risk, where any setback on trials, guidance, or integration could weigh on valuation.

What's in the News

BioMarin discontinued dosing and enrollment in Phase 2 trials of VOXZOGO in Turner syndrome, SHOX deficiency, and Aggrecan deficiency after several slipped capital femoral epiphysis events were seen in two investigator sponsored trials. The company reported no such events in its own Phase 2 studies or in more than 5,000 treated achondroplasia patients and other VOXZOGO programs. The CANOPY trials in Noonan syndrome and most idiopathic short stature patients are continuing as planned (Key Developments).
New VOXZOGO data in children with achondroplasia are set to be presented at the 2026 ACMG Annual Clinical Genetics Meeting. These data include results suggesting early treatment before age 2 is associated with multi year growth improvements, changes in body proportionality, and arm span versus untreated children, alongside a detailed safety profile and dosing guidance (Key Developments).
The U.S. FDA approved a supplemental Biologics License Application for PALYNZIQ to include pediatric patients 12 years and older with phenylketonuria, based on Phase 3 PEGASUS study data. The product is distributed under a REMS program due to anaphylaxis risk observed in clinical trials (Key Developments).
BioMarin issued full year 2026 earnings guidance, expecting total revenue between US$3.325b and US$3.425b (Key Developments).
Health Canada granted a Notice of Compliance with Conditions for PrVOXZOGO, providing an approved treatment option for eligible achondroplasia patients in Canada. This follows prior VOXZOGO approvals in the U.S. and European Union (Key Developments).

Valuation Changes

Fair Value: updated slightly lower from $88.96 to $88.87 per share, reflecting a marginal adjustment to the blended valuation model.
Discount Rate: trimmed modestly from 7.16% to 7.13%, indicating a small change in the risk or return assumptions used in the model.
Revenue Growth: held effectively unchanged at about 14.96%, suggesting no material shift in long term top line expectations.
Net Profit Margin: kept stable at roughly 28.57%, with only a rounding level adjustment in the model.
Future P/E: revised slightly lower from 15.11x to 15.08x, pointing to a minor reset in the multiple applied to expected earnings.

8 views

Key Takeaways

Expanding global demand, new therapies, and strategic acquisitions strengthen BioMarin's revenue growth, market reach, and future pipeline potential.
Operational efficiency, disciplined cost management, and regulatory advantages support sustained profitability and long-term margin stability.
Revenue and earnings face mounting risks from escalating competition, pricing pressures, pipeline dependency, heightened expenses, and regulatory uncertainty across key products and markets.

Catalysts

About BioMarin Pharmaceutical

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.What are the underlying business or industry changes driving this perspective?

Strong year-over-year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top-line revenue growth.
Accelerated pipeline advancement, including late-stage programs (BMN 333 for achondroplasia, BMN 401 for ENPP1 deficiency, and label expansions for PALYNZIQ), positions BioMarin to capitalize on growing patient pools through earlier and more accurate genetic identification, which should expand future addressable markets and boost revenue.
Recent acquisition of Inozyme and ongoing business development initiatives broaden BioMarin's enzyme therapy portfolio and introduce new high-value therapies targeting severe unmet needs, enhancing diversification and durability of revenue streams over the long term.
Company's operational leverage and disciplined cost management as new products move from R&D to commercial stage-combined with efforts to improve patient adherence and maximize market penetration-are likely to support margin expansion and drive earnings growth.
Supportive regulatory environment for orphan drugs, including accelerated pathways and favorable exclusivity, provides revenue protection and mitigates risks from generic/biosimilar competition, thereby underpinning long-term profitability and net margin stability.

BioMarin Pharmaceutical Earnings and Revenue Growth

BioMarin Pharmaceutical Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming BioMarin Pharmaceutical's revenue will grow by 15.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 10.8% today to 28.6% in 3 years time.
Analysts expect earnings to reach $1.4 billion (and earnings per share of $7.24) by about April 2029, up from $348.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.0 billion in earnings, and the most bearish expecting $1.0 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.2x on those 2029 earnings, down from 31.1x today. This future PE is greater than the current PE for the US Biotechs industry at 15.1x.
Analysts expect the number of shares outstanding to grow by 0.29% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.13%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Intensifying competition in the rare disease and skeletal growth disorder market-such as the development of competing long-acting CNP therapies and potential combination treatments with growth hormone-may limit future revenue growth of BioMarin's key asset VOXZOGO and upcoming agents like BMN 333, raising risks of price erosion and reduced market share. (Likely impacts: revenue, net margins)
Ongoing and anticipated increases in R&D and SG&A expenses related to pipeline advancement, business development (e.g., Inozyme acquisition integration), and commercial expansion could compress operating margins and result in lower future earnings, especially if anticipated product approvals and launches are delayed or unsuccessful. (Likely impacts: net margins, earnings)
Secular pricing pressure and order timing outside the U.S. (noted in revised forward guidance), as well as the backdrop of global reimbursement reform and payer scrutiny for rare disease treatments, may weaken BioMarin's ability to achieve premium pricing and sustainable top-line growth. (Likely impacts: revenue, net margins)
Portfolio concentration risk remains elevated, with current and upcoming revenue disproportionately dependent on a limited number of products (VOXZOGO, PALYNZIQ, VIMIZIM); any issues such as loss of exclusivity, unfavorable intellectual property decisions (e.g., ongoing litigation/IPR&D review, orphan drug extension disputes), or failure to achieve regulatory milestones could result in abrupt revenue declines and higher volatility in earnings. (Likely impacts: revenue, earnings)
Regulatory risks-including the need for successful Phase II/III and pivotal trials, evolving requirements for functional and clinical endpoints (as seen for BMN 401/ENERGY III), and potential delays or negative outcomes in ongoing ITC proceedings, FDA reviews, and international submissions-may increase costs, delay market entry, or limit future approvals, thereby slowing prospective revenue and profit growth. (Likely impacts: revenue, net margins, earnings)

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $88.87 for BioMarin Pharmaceutical based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $120.0, and the most bearish reporting a price target of just $55.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.9 billion, earnings will come to $1.4 billion, and it would be trading on a PE ratio of 15.2x, assuming you use a discount rate of 7.1%.
Given the current share price of $56.49, the analyst price target of $88.87 is 36.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on BioMarin Pharmaceutical?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead